New hope for Tough-to-Treat prostate cancer: major trial tests multiple drug combos

NCT ID NCT02861573

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing the safety and effectiveness of several different drug combinations, all built around an immunotherapy drug called pembrolizumab, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. It will enroll about 1,200 participants across ten different treatment groups, each testing a unique combination of drugs. The main goals are to see if these combinations can shrink tumors, lower a key prostate cancer marker (PSA), and are safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Call for Information (Investigational Site 0008)
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Call for Information (Investigational Site 0016)
RECRUITING

Seattle, Washington, 98109, United States
Call for Information (Investigational Site 0019)
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Call for Information (Investigational Site 2041)
RECRUITING

Aurora, Colorado, 80045, United States
Call for Information (Investigational Site 2090)
RECRUITING

Germantown, Tennessee, 38138, United States
Call for Information (Investigational Site 2091)
RECRUITING

Cleveland, Ohio, 44195, United States
Call for Information (Investigational Site 2094)
RECRUITING

Portland, Oregon, 97239, United States
MSD Australia
RECRUITING

North Ryde, Australia

Contact Phone: •••-•••-••••
MSD Comercializadora, S. de R.L. de C.V.
RECRUITING

Mexico City, Mexico

Contact Phone: •••-•••-••••
MSD Denmark
RECRUITING

Glostrup Municipality, Denmark

Contact Phone: •••-•••-••••
MSD France
RECRUITING

Paris, France

Contact Phone: •••-•••-••••
MSD Ireland (Human Health) Ltd.
RECRUITING

Dublin, Ireland

Contact Phone: •••-•••-••••
MSD Italia S.r.l.
RECRUITING

Rome, Italy

Contact Phone: •••-•••-••••
MSD Polska Sp. Z o.o.
RECRUITING

Warsaw, Poland

Contact Phone: •••-•••-••••
MSD Sweden
RECRUITING

Stockholm, Sweden

Contact Phone: •••-•••-••••
Merck Canada
RECRUITING

Kirkland, Quebec, H9H 4M7, Canada

Contact Phone: •••-•••-••••
Merck Sharp & Dohme (New Zealand) Ltd.,
RECRUITING

Auckland, New Zealand

Contact Phone: •••-•••-••••
Merck Sharp & Dohme BV
RECRUITING

Haarlem, Netherlands

Contact Phone: •••-•••-••••
Merck Sharp & Dohme Ilaclari Ltd. Sti
RECRUITING

Istanbul, Turkey (Türkiye)

Contact Phone: •••-•••-••••
Merck Sharp & Dohme Ltd.
RECRUITING

London, United Kingdom

Contact Phone: •••-•••-••••
Merck Sharp and Dohme de Espana S.A.
RECRUITING

Madrid, Spain

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER